Acacia Pharma Ltd. says it is business as usual despite being left gobsmacked by a rejection from the FDA for its post-operative nausea and vomiting (PONV) therapy Barhemsys (low-dose amisulpride injection) due to concerns about a facility of its contract drug manufacturer.
The UK firm, which listed on the Euronext stock exchange in Brussels in March this year, has been hit with...








